FCM
FNCH

Farallon Capital Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Farallon Capital Management’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,178
Closed -$2.61M – 316
2021
Q2 		$2.61M Sell
6,178
-6,822
-52% -$2.95M 0.01% 202
2021
Q1 		$6.21M Buy
+13,000
New +$6.62M 0.03% 173

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Farallon Capital Management's FNCH Position: Q3 2021 in Review

Farallon Capital Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q3 2021, closing a stake of 6,178 shares — an estimated $2.61M sold.

Farallon Capital Management first reported a position in FNCH in Q1 2021 and held it in 2 quarters. The position peaked at $6.21M in Q1 2021. 44 funds tracked by Wall St. Rank hold FNCH as of Q3 2021.

  • Farallon Capital Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Farallon Capital Management sold 6,178 Finch Therapeutics Group, Inc. Common Stock shares in Q3 2021, an estimated $2.61M.
  • Farallon Capital Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Farallon Capital Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $6.21M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q3 2021.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.